公开(公告)号：US11629122B2

公开(公告)日：2023-04-18

申请号：US16616148

申请日：2018-05-24

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Kyoji Tsuchikama ,  Yasuaki Anami ,  Chisato Tsuchikama ,  Ningyang Zhang ,  Zhiqiang An

IPC: C07C247/04 ,  A61K47/68 ,  A61P35/00 ,  A61K31/40 ,  C07D209/20 ,  C07D403/12 ,  A61K45/06

Abstract: In one aspect, the present disclosure provides compounds of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula (V): wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.

公开(公告)号：US09725520B2

公开(公告)日：2017-08-08

申请号：US14774808

申请日：2014-03-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan Zhang ,  Zhiqiang An

IPC: C07K16/32 ,  G01N33/574 ,  A61F7/10 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K39/00

CPC classification number: C07K16/32 ,  A61F7/10 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57484 ,  G01N33/57492

Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

公开(公告)号：US12202895B2

公开(公告)日：2025-01-21

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang An ,  Chengcheng Zhang ,  Ningyan Zhang ,  Xun Gui ,  Mi Deng ,  Tao Huang ,  Qiang Liu ,  X. Charlene Liao

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61K51/10 ,  A61P35/02 ,  G01N33/574

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

公开(公告)号：US12084403B2

公开(公告)日：2024-09-10

申请号：US18173413

申请日：2023-02-23

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Kyoji Tsuchikama ,  Yasuaki Anami ,  Chisato Tsuchikama ,  Ningyang Zhang ,  Zhiqiang An

IPC: C07C247/04 ,  A61K31/40 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07D209/20 ,  C07D403/12

CPC classification number: C07C247/04 ,  A61K31/40 ,  A61K47/6889 ,  A61P35/00 ,  C07D209/20 ,  C07D403/12 ,  A61K45/06

Abstract: In one aspect, the present disclosure provides compounds of the formula:




wherein the variables are as defined herein.

In another aspect, the present disclosure provides compounds of the formula:




wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.

公开(公告)号：US11377491B2

公开(公告)日：2022-07-05

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene Liao ,  Qiang Liu ,  Zhiqiang An ,  Ningyan Zhang ,  Xun Gui ,  Chengcheng Zhang ,  Mi Deng ,  Jingjing Xie

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

公开(公告)号：US10889637B2

公开(公告)日：2021-01-12

申请号：US16078990

申请日：2017-02-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jean X. Jiang ,  Zhiqiang An ,  Ningyan Zhang ,  Wei Xiong ,  Manuel A. Riquelme ,  Sumin Gu ,  Naomi Ledene Sayre

IPC: C07K16/18 ,  A61P25/28 ,  A61P19/10 ,  A61K39/395 ,  A61P35/00

Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

公开(公告)号：US10358501B2

公开(公告)日：2019-07-23

申请号：US15643690

申请日：2017-07-07

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan Zhang ,  Zhiqiang An

IPC: C07K16/32 ,  G01N33/574 ,  A61F7/10 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K39/00

Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

公开(公告)号：US12152071B2

公开(公告)日：2024-11-26

申请号：US17096280

申请日：2020-11-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan Zhang ,  Zhiqiang An ,  Anil K. Sood

IPC: C07K16/22 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00 ,  C12N15/113 ,  G01N33/574

Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

公开(公告)号：US11912758B2

公开(公告)日：2024-02-27

申请号：US17146187

申请日：2021-01-11

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jean X. Jiang ,  Zhiqiang An ,  Ningyan Zhang ,  Wei Xiong ,  Manuel A. Riquelme ,  Sumin Gu ,  Naomi Ledene Sayre

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00 ,  A61P25/28 ,  A61P19/10

CPC classification number: C07K16/18 ,  A61K39/395 ,  A61P19/10 ,  A61P25/28 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76

Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

公开(公告)号：US11498963B2

公开(公告)日：2022-11-15

申请号：US16678049

申请日：2019-11-08

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng Zhang ,  Mi Deng ,  Wei Xiong ,  Zhiqiang An ,  Ningyan Zhang ,  Xun Gui ,  Junke Zheng

IPC: A61K39/00 ,  C07K16/28 ,  G01N33/574 ,  C12N15/113 ,  A61P35/02 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.